© 1997 by European Society of Cardiology
Copyright © 1997, European Society of Cardiology
Arterial gene transfer of acidic fibroblast growth factor for therapeutic angiogenesis in vivo: critical role of secretion signal in use of naked DNA
Department of Medicine (Cardiology) and Biomedical Research, St. Elizabeth's Medical, Center of Boston, Tufts University School of Medicine, 736 Cambridge St., Boston, MA 02135, USA
* Corresponding author. Tel.: +1 617 7892392; Fax: +1 617 7895029; E-mail: jisner@opal.tufts.edu
Objective: Previous studies have demonstrated that arterial gene transfer of naked DNA encoding for a secreted protein may permit modulation of the host phenotype despite a low transfection efficiency. Acidic fibroblast growth factor (aFGF) is an angiogenic growth factor, but is not secreted by intact cells. In the current study, we investigated the hypothesis that addition of a hydrophobic leader sequence to achieve active secretion of the gene product would permit therapeutic angiogenesis following arterial gene transfer of naked DNA encoding for aFGF. Methods: Ten days following surgical induction of unilateral hindlimb ischemia, New Zealand white rabbits were randomized to intra-arterial gene transfer with one of three plasmids: p267 (encoding non-secreted aFGF, n = 10), pMJ35 (encoding secreted aFGF) (n = 10), or 500 µg of pGSVLacZ (control, n = 10) (500 µg each). All animals were studied at 30 days post-gene transfer for evidence of therapeutic angiogenesis. Results: pMJ35 transfectants had more angiographically visible collaterals (angiographic score=0.76±0.02) than either p267 (0.55±0.02, p<0.01) or LacZ (0.47±0.02, p<0.001). Limb blood pressure ratio for pMJ35 was 0.88±0.02 vs. 0.68±0.04 for p267 (p<0.01) and 0.57±0.04 for LacZ (p<0.001). Vascular resistance was significantly lower in the pMJ35 group, compared with that in pGSVLacZ group, both in resting state (3.2±0.4 vs. 7.4±1.4 respectively, p<0.05) and after the administration of nitroprusside. Capillary density (per mm2) was also superior in pMJ35 group (274±10) vs. p267 (204±9, p<0.01) and LacZ (177±6, p<0.001). Conclusion: The paracrine effects of a secreted gene product may obviate the need for adjunctive vectors in strategies of arterial gene therapy.
KEYWORDS Acidic fibroblast growth factor (aFGF); Gene therapy; Angiogenesis; Signal peptide
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. E. Epstein, E. Stabile, T. Kinnaird, C. W. Lee, L. Clavijo, and M. S. Burnett Janus Phenomenon: The Interrelated Tradeoffs Inherent in Therapies Designed to Enhance Collateral Formation and Those Designed to Inhibit Atherogenesis Circulation, June 15, 2004; 109(23): 2826 - 2831. [Full Text] [PDF]
|
|
|
|
 |
|
 J. C Hershey, H. A Corcoran, E. P Baskin, D. B Gilberto, X. Mao, K. A Thomas, and J. J Cook Enhanced hindlimb collateralization induced by acidic fibroblast growth factor is dependent upon femoral artery extraction Cardiovasc Res, October 1, 2003; 59(4): 997 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Freedman and J. M. Isner Therapeutic Angiogenesis for Coronary Artery Disease Ann Intern Med, January 1, 2002; 136(1): 54 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Isner, P. R. Vale, J. F. Symes, and D. W. Losordo Assessment of Risks Associated With Cardiovascular Gene Therapy in Human Subjects Circ. Res., August 31, 2001; 89(5): 389 - 400. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Meyerson, C. L. Skelly, M. A. Curi, and L. B. Schwartz Gene Therapy for Cardiovascular Disease Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 2000; 4(4): 289 - 300. [Abstract] [PDF]
|
|
|
|
|
|
K. A. Vincent, K.-G. Shyu, Y. Luo, M. Magner, R. A. Tio, C. Jiang, M. A. Goldberg, G. Y. Akita, R. J. Gregory, and J. M. Isner Angiogenesis Is Induced in a Rabbit Model of Hindlimb Ischemia by Naked DNA Encoding an HIF-1{alpha}/VP16 Hybrid Transcription Factor Circulation, October 31, 2000; 102(18): 2255 - 2261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Fernandez, A. Buehler, S. Wolfram, S. Kostin, G. Espanion, W. M. Franz, H. Niemann, P. A. Doevendans, W. Schaper, and R. Zimmermann Transgenic Myocardial Overexpression of Fibroblast Growth Factor-1 Increases Coronary Artery Density and Branching Circ. Res., August 4, 2000; 87(3): 207 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. O Hiltunen, M. P Turunen, M. Laitinen, and S. Yla-Herttuala Insights into the molecular pathogenesis of atherosclerosis and therapeutic strategies using gene transfer Vascular Medicine, February 1, 2000; 5(1): 41 - 48. [Abstract] [PDF]
|
|
|
|
 |
|
 L. M. Mir, M. F. Bureau, J. Gehl, R. Rangara, D. Rouy, J.-M. Caillaud, P. Delaere, D. Branellec, B. Schwartz, and D. Scherman High-efficiency gene transfer into skeletal muscle mediated by electric pulses PNAS, April 13, 1999; 96(8): 4262 - 4267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. Favaloro Landmarks in the Development of Coronary Artery Bypass Surgery Circulation, August 4, 1998; 98(5): 466 - 478. [Full Text] [PDF]
|
|
|
|
|
|
E. Van Belle, B. Witzenbichler, D. Chen, M. Silver, L. Chang, R. Schwall, and J. M. Isner Potentiated Angiogenic Effect of Scatter Factor/Hepatocyte Growth Factor via Induction of Vascular Endothelial Growth Factor : The Case for Paracrine Amplification of Angiogenesis Circulation, February 3, 1998; 97(4): 381 - 390. [Abstract] [Full Text] [PDF]
|
|